Brolucizumab for Neovascular Age-Related Macular Degeneration (BEL Study)

PURPOSE: This retrospective observational study reports early results on a cohort of neovascular age-related macular degeneration (nAMD) patients switched to brolucizumab, a recently approved anti-vascular endothelial growth factor (anti-VEGF). PATIENTS AND METHODS: We evaluated best-corrected visua...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Cleemput, Liesbeth, Peeters, Freya, Jacob, Julie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094460/
https://www.ncbi.nlm.nih.gov/pubmed/37064958
http://dx.doi.org/10.2147/OPTH.S402090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094460/
https://www.ncbi.nlm.nih.gov/pubmed/37064958
http://dx.doi.org/10.2147/OPTH.S402090

Ejemplares similares